Strategies to minimize the impact of presence of residual solvents in APIs

Similar documents
GC METHOD FOR QUANTITATIVE DETERMINATION OF RESIDUAL 2-(2-CHLOROETHOXY)ETHANOL (CEE) AND N-METHYL-2-PYRROLIDINONE (NMP) IN QUETIAPINE

Swiss Medic Training Sampling

The Use of the ACQUITY QDa Detector for a Selective, Sensitive, and Robust Quantitative Method for a Potential Genotoxic Impurity

Simultaneous Estimation of Residual Solvents (Isopropyl Alcohol and Dichloromethane) in Dosage Form by GC-HS-FID

Fast Analysis of USP 467 Residual Solvents using the Agilent 7890A GC and Low Thermal Mass (LTM) System

The Analysis of Residual Solvents in Pharmaceutical Products Using GC-VUV and Static Headspace

The Determination of Residual Solvents in Pharmaceuticals Using the Agilent G1888 Network Headspace Sampler Application

Trace analysis of mesityl oxide and diacetone alcohol in pharmaceuticals by capillary gas chromatography with flame ionization detection

Simultaneous dual capillary column headspace GC with flame ionization confirmation and quantification according to USP <467> Application Note

ICH M7 Impact on DMF Review Process. David Green Quality Assessment Lead (acting) CDER/OPQ/ONDP/DLCAPI November 4, 2015

DETERMINATION OF ORGANIC VOLATILE IMPURITIES IN NEPAFENAC BY GC METHOD

Residual Solvents in Pharmaceuticals by USP Chapter <467> Methodology

ASEAN GUIDELINES FOR VALIDATION OF ANALYTICAL PROCEDURES

Starting Materials For Active Substances

Development and Validation of a Headspace Gas Chromatographic Method for determination of Residual Solvents in Bosentan Monohydrate.

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

Head of the Certification of Substances Division, EDQM

Introduction to Pharmaceutical Chemical Analysis

A Fast and Sensitive Method for Residual Hydrazine Analysis in Pharmaceutical Samples

PART II VIII. CONCERNING CHEMICAL. PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION FOR RADIOPHARMACEUTICAL PRODUCTS.

A Capillary Gas Chromatographic Procedure for the Analysis of Nine Common Residual Solvents in Water-Insoluble Bulk Pharmaceuticals

Cleaning Memo for January 2017 A Critique of the APIC Guideline

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) GUIDELINE ON RADIOPHARMACEUTICALS

Methyl Salicylate Technical Package

Fast, Quantitative Analysis of Residual Solvents in Cannabis Concentrates

Low-level Determination of 4-Hydrazino Benzoic Acid in Drug Substance by High Performance Liquid Chromatography/Mass Spectrometry

Introducing New Functionalities in Liquid Stationary Phases in GC Columns for Confirming Organic Volatile Impurity Testing in Pharmaceutical Products.

Journal of Chemical and Pharmaceutical Research

The determination of residual solvents in pharmaceuticals using the Agilent G1888 headspace/6890n GC/5975 inert MSD system Application Note

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

Rosemary extract liquid

A Generic Method for the Analysis of Residual Solvents in Pharmaceuticals Using Static Headspace-GC-FID/MS

Analyzing Residual Solvents in Pharmaceutical Products Using GC Headspace with Valve-and-Loop Sampling

A Laboratory Guide to Method Validation, (Eurachem).

serve the goal of analytical lmethod Its data reveals the quality, reliability and consistency of

Stability of pharmaceutical preparations

Chromatographic Methods of Analysis Section: 5 Gas Chromatography (GC) Prof. Tarek A. Fayed

Department of Post graduate Chemistry, SVRM College (Autonomous) Nagaram, Andhra Pradesh, India Corresponding Author:

A New Ether Process Solvent: Cyclopentyl methyl ether (CPME) for Green Chemistry and Process Innovation

Study of Residual Solvents in Various Matrices by Static Headspace

The Isosorbide Mononitrate Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

Nanomaterials under REACH

NaturalFacts. Introducing our team. New product announcements, specials and information from New Roots Herbal. April 2009

USP<467> residual solvents

Regulation 6 months experience. Sonia Ribeiro 1-2 June 2010, London, UK

4023 Synthesis of cyclopentanone-2-carboxylic acid ethyl ester from adipic acid diethyl ester

Method for Characterization of Gum Rosin by Capillary Gas Chromatography

Additives, Process Chemicals and Raw Materials (Corrosive) Group Standard HSR002491

ISSN: ; CODEN ECJHAO E-Journal of Chemistry , 7(2),

Data Sharing Initiatives Dr Andy Teasdale

5072 CHEMISTRY (NEW PAPERS WITH SPA) TOPIC 1: EXPERIMENTAL CHEMISTRY 5067 CHEMISTRY (NEW PAPERS WITH PRACTICAL EXAM) TOPIC 1: EXPERIMENTAL CHEMISTRY

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Guidance for Industry M4: The CTD General Questions and Answers

why open access publication of stability date is essential Mark Santillo Regional QA Officer SW England

ICH Topic M 4 Common Technical Document for the Registration of Pharmaceuticals for Human Use Questions and Answers. Step 5

Highly sensitive quantitative estimation of genotoxic impurities from API and drug formulation using LC/MS/MS

Introduction to Impurity Profile

BRIEFING. Pharmacopeial Discussion Group Sign Off Document Attributes EP JP USP Definition Loss on drying Readily carbonizable substances

CH 2252 Instrumental Methods of Analysis Unit V Gas Chromatography. M. Subramanian

Principles of Gas- Chromatography (GC)

CHEM 429 / 529 Chemical Separation Techniques

M4 Implementation Working Group Questions & Answers (R3) Current version dated June 10, 2004

Direct Swabbing and Surface Recovery with Ion Trap Mobility Spectrometry

Solvents (Flammable) Group Standard HSR002650

Introduction to E&Ls 1

A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation

Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC

CTD General Questions and Answers

Cleaning Validation of Equipments in Bulk Drug Manufacturing Facility for Lignocaine Hydrochloride by using HPLC

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

Analysis of Residual Solvents in Pharmaceuticals (USP<467>) with Shimadzu GC-2010 Plus and HS-10 Headspace Sampler

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

PRINCIPLES AND APPLICATION OF CHROMATOGRAPHY. Dr. P. Jayachandra Reddy Mpharm PhD Principal & professor KTPC

The Claviature of Gas Analysis

Technical Paper. Spray Granulation Gives Solid Materials Customized. The properties of spray-granulated products can be as varied as their appearance

Development and Validation of GC-FID Method for the Quantification of N-Iodosuccinimide

[ 11 C]MePPEP FOR INJECTION: CHEMISTRY, MANUFACTURING AND CONTROLS

Identification, Quantitation and Control of Trace Level Genotoxic Impurities in Organic Synthesis Intermediates and Final Products

Technical instructions on how to report substance identity information for CICPs in IUCLID 6

Analytical Method Validation: An Updated Review

C18 Column. Care & Use Sheet

International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: , ISSN(Online): Vol.9, No.7, pp , 2016

Quality by Design and Analytical Methods

CHEM 200 Chapter 2 General Work Practices

SYNOPSIS OF CHANGES TO BC LABORATORY MANUAL, MARCH 2017

[ 11 C]NNC 112 FOR INJECTION: CHEMISTRY, MANUFACTURING AND CONTROLS

THERAPEUTIC GOODS SAMPLING Application to Tablet Manufacture and Ingredients. David Edmonds CMC Regulatory

Concept of Elemental Impurities (EI) assessment in finished dosage forms by total extraction testing

Validation of analytical methods. Adrian Covaci Toxicological Center, University of Antwerp

Tar analysis by Solid Phase Adsorption (SPA) associated with Thermal Desorption (TD) and Gas Chromatography (GC) analysis

Additionally, minor editorial changes have been made to update the monograph to current USP style.

2] The plate height in chromatography is best described as 2

International Journal of Medicine and Pharmaceutical Research

2. Pharmaceutical industry

International Journal of Pharmacy and Pharmaceutical Sciences ISSN Vol 2, Suppl 3, 2010

CHAPTER 6 GAS CHROMATOGRAPHY

Setting Attainable and Practical Particle Size Specifications

Perfluorinated Alkyl Acids (PFAA) in Water by LC/MS/MS - PBM

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

CHIRAL SEPARATION USING THIN LAYER CHROMATOGRAPHY

Transcription:

CBC-PROCOS S.p.A. Strategies to minimize the impact of presence of residual solvents in APIs DamianaGentili Qualified Person, Quality Unit Director CBC ProcosS.p.A. Pavia, 02 nd October 2015 slide# 1

Agenda Definitions Guidelines approach DMF Sections Main References Strategy of control Equipments Impact on physical properties API level Post approval changes Pavia, 02 nd October 2015 slide# 2

Definitions Organic volatile chemicals: used or produced in the manufacture of drug substances or excipients, or in the preparation of drug products not completely removed by practical manufacturing techniques. Pavia, 02 nd October 2015 slide# 3

Relevant CTD sections for solvents MODULE 3 Pavia, 02 nd October 2015 slide# 4

Main relevant API DMF sections for solvents 3.2.S.2.2 Description of manufacturing process and in process control 3.2.S.3.2 Impurities 3.2.S.4.1 Specification 3.2.S.4.2 Analytical procedure 3.2.S.4.3 Validation of analytical procedure 3.2.S.4.5 Justification of specification Pavia, 02 nd October 2015 slide# 5

Pavia, 02 nd October 2015 slide# 6 Where to start? ICH guideline Q3C http://www.ich.org/home.html USP <467> (Chemical tests Residual solvents) EP <5.4> Limiting residual solvents level in active substances, excipient and medicinal products Annexes to: CPMP/ICH/283/95 Impurities: Guidelines for residual solvents CVMP/VICH/502/99 Guidelines on impurities: Residual solvents But.more if genotoxic compounds

Guideline approach Classificationof solventsbasedon their severity Class 1 solvents: Solvents to be avoided Class 2 solvents: Solvents to be limited Class 3 solvents: Solvents with low toxic potential Others Limit definition ESTABLISHED IN TABLES (based on daily dosage of 10 g) NO FURTHER CALCULATION IS REQUIRED CASE BY CASE : ON PDE and DAILY DOSAGE Pavia, 02 nd October 2015 slide# 7

Recent Updatings (June 2015) o MIBK will be placed into Class 2 (limited by health-basis) from Class 3 (no health-based). o New solvent Triethylaminehas also been included in Class 3. New limit: 0,5% Q&A EDQM (320 ppm for 10 g daily dose, based on a Permitted Daily Exposure of 3.2 mg/day) Pavia, 02 nd October 2015 slide# 8

Pavia, 02 nd October 2015 slide# 9

Strategy of control & impact at API level for solvents used in manufacturing Knowledge of the solvents used in the manufacturing process(and preferably in the key starting material) Evaluation of the capability of the manufacturing process to remove them by: Distillation Drying Class 2, 3 if demonstration of absence at intermediate or API level ( 10%ICH limit) NO NEED OF ROUTINE ANALYTICAL CHECK Scientific identification of solvents «likely to be present» to be included in the API specification Pavia, 02 nd October 2015 slide# 10

Strategy of control & impact at API level: solvents used Pavia, 02 nd October 2015 slide# 11 API specifications Class 1: normally absent Class 2: listed with ICH limits, GC routinely tested Class 3 (only): monitored by LOD If Class 2 + Class 3 solvents: listed with ICH by GC + LOD or only GC Other solvents (only): listed with justified limit; skip test could be accepted

Strategy of control & impact at API level : toxic solvents as «by products» or used Limits set as for TTC approach (ICH M7 or Guideline on the limits of genotoxic impurities' EMEA/CHMP/QWP/251344/2006), GC validated analythical method Routinely check, if present If introduced at intermediates :demonstrated 30% below the ICH limit on 6 pilot or 3 industrial batches for API, API no routine test is required (Skip test)+ limit at intermediate If introduced at final stage :skip test if demonstrated 30% below the ICH limit at API Pavia, 02 nd October 2015 slide# 12

Strategy of control & impact at API level: example of toxic solvents as by products Benzene Acetone Methanol Toluene Epthane Mesityl oxide Acetone Pavia, 02 nd October 2015 slide# 13

Equipments GC systems with different injection mode and detectors Injection mode Liquid (direct) injection Head space (HS) Detectors Flame ionization detector (FID) Thermal conductivity detector (TCD) Mass spectrometer (MS) LC systemsequipped with UV/PDA detectors for particular applications (es. Formamide) Pavia, 02 nd October 2015 slide# 14

Solvents may impact on physical properties of API Caking (the formation of lumps or hard blocks which reduce the flowability of solids) is produced by bulk cohesive strength between particles named as solid bonds Residual of solvents facilitate to create the solid bonds as for the follow: Pavia, 02 nd October 2015 slide# 15

Impact on physical properties of API: Solid bond bridge caking a) Sinter bridge, melt bridge Solid partially melt and solidify again. During melting and solidification solid bonds are formed. Temperatures of 1/3 2/3 of melting temperature cause solid bond during long time storages b) Catalyzed solid, crysallising binder Solid partially dissolves into the water or solvent adsorbed onto the surface and then precipitate again. During dissolution and precipitation solid bonds are formed 0.1% - 0.5% of water / solvent are enough for solid bonds formation. Pavia, 02 nd October 2015 slide# 16 Università degli Studi di Pavia, Dipartimento di Chimica Fisica

Post approval changes for solvent EU vs US: an evaluation Change description US EU Solvent change before final intermediate Solvent change after final intermediate CBE 30 PAS II or IB II or IB Solvent change with impact on impurity profile PAS II Guidance for Industry -Changes to an approved NDA or ANDA Reg CE 1234/2008 Pavia, 02 nd October 2015 slide# 17

QUESTIONS? Thanksfor yourattention! gentili@procos.it Pavia, 02 nd October 2015 slide# 18